26 January 2017 - PHARMAC is pleased to announce the approval of an agreement with Allergan to amend the contractual terms of listing for clostridium botulinum type A toxin (Botox) 100 u vial in DHB hospitals.

This was the subject of a consultation letter dated 6 December 2016.  The effect of the decision is that:

• The net price for Botox 100 u vial will reduce from 1 April 2017 via a confidential rebate applied to all sales to DHB hospitals.
  
• Botox will have protection from purchase price reduction, delisting and application of indication restrictions until 31 March 2020.
  
• There will be no changes to the listing of the other brand of clostridium botulinum type A toxin (Dysport) currently listed in the Hospital Medicines List for use in DHB hospitals.
  
• Botox and Dysport have different potencies, meaning doses are different and prices are not directly comparable unit for unit. At a dose equivalency of 3:1 1 2 Botox will be the most cost effective treatment option for DHBs, compared to Dysport.
  

Read PHARMAC press release